Richard J Auchus, MD, PhD, Details Pivotal Phase 3 Trial That Supported FDA Approval of Crinecerfont for Congenital Adrenal Hyperplasia

Richard Auchus, MD, PhD, a preeminent steroid biologist who has worked on improving treatment for people with congenital adrenal hyperplasia (CAH) for 2 decades, details the CAHtalyst phase 3 clinical trial of crinecerfont in adults that served as the foundation for the December 13, 2024, FDA approval of the corticotropin-releasing factor-1 (CRF-1) antagonist to treat classic CAH in adults and children. Crinecerfont effectively blocks anterior pituitary release of ACTH and thus the downstream overproduction of adrenal androgens. The unique study comprises half of the largest-ever clinical trial program in pediatric and adult patients with classic CAH.

Richard J Auchus, MD, PhD, is the James A. Shayman and Andrea S. Kevrick professor of translational medicine, professor of internal medicine, and professor of pharmacology at the University of Michigan Medical School in Ann Arbor, MI. His areas of work include molecular and genetic mechanisms of human hypertension, improved diagnostic studies and management in primary aldosteronism and Cushing syndromes, modifier genes in 21-hydroxylase deficiency, cardiovascular disease in polycystic ovary syndrome, and the endocrinology of traumatic brain injury.